Menu ×


Bivalirudin and desmopressin Market : Global Demand Analysis & Opportunity Outlook 2024

  • Report ID: 266
  • Text Size:

Extensive insights into the Growth of Bivalirudin and desmopressin Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

Bivalirudin and desmopressin Market Overview

Bivalirudin is a thrombin –inhibiting oligopeptide that was developed through rational drug as a hirudin analogue.  It is a thrombin inhibitor consisting of 20 –amino acid structure combining a carboxy-terminal region that recognizes thrombin’s fibrin (ogen)-  binding sate.  It works by blocking of the formation of blood clots. Likewise, desmopressin is an antidiuretic harmone. It works by causing the kidneys to produce less urine. Bivalirudin is used as an anticoagulant in the patients with unstable angina who are undergoing percutaneous transluminal coronary angioplasty (PTCA) and in patients undergoing percutaneous coronary intervention (PCI). Moreover, Bivalirudin is used in conjuction with other medicines. Further, desmopressin is used to manage temporarily increased thirst and urination caused by head injury.

Market Size and Forecast

The market is expected to increase significantly over the forecast period 2017-2024. The bivalirudin is facing increased demand due to its application in the treatment of coronary artery disease and cancer.  Likewise, the demand for desmopressin is increasing due to its use in bedtime wetting and nocturia. CLICK TO DOWNLOAD  SAMPLE REPORT

Market Segmentation:

Our in depth analysis of the bivalirudin and desmopressin market includes the following segments:

By Use:

  • Percutaneous Transluminal Coronary Angioplasty (PTCA) Procedures
  • Percutaneous Coronary Intervention (PCI) Procedures
  • Others

The global bivalirudin and desmopressin market is further classified on the basis of region as follows:

By Region:

  • North America (United States, Canada), Market size, Y-O-Y growth Market size, Y-O-Y growth & Opportunity Analysis, Future forecast & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Sweden, Finland), Poland, Russia, Rest of Europe), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis

Bivalirudin and desmopressin Market

Growth Drivers and Challenges

The market growth is driven by the rise in the number of the cases of cardiovascular diseases. According to the American Heart Association, the number of the adults living with the heart failure has increased from 5.7 million (2009-12) to about 6.5 million (2011-2014). Further, the cardiovascular diseases are on rise thereby leading to the increased number of deaths across the world. The cardiovascular diseases include coronary artery disease, high blood pressure and stroke. The patients with ST-elevation myocardial infarction (STEMI) is often achieved via primary percutaneous coronary intervention (PCI), thus reducing major adverse cardiovascular diseases. Adjunctive antithrombotic and antiplatelet therapies are used during PCI to reduce MACE rates. The most commonly used agents include low unfractioned heparin. These agents reduce the rates of peri-procedural ischemic and thrombotic events, but these agents produce complications in the form of increased bleeding, but bivalirudin has emerged as a safe alternative to heparin and helps in reducing the risk of coronary artery disease. Moreover, bivalirudin has advantages over the heparin including reduced rates of mortality, cardiovascular mortality and major bleeding events. Therefore, this has led to the adoption of bivalirudin as a drug for the treatment of coronary artery disease, thus leading to the expansion of the bivalirudin market.  The increase in the number of cancer patients is another reason that is driving the growth of bivalirudin market. According to the World Health Organization (WHO), approximately 14 million cases came into the light in 2012. Moreover, the cancer is second leading cause of the death globally, and was responsible for 8.8 million deaths in 2015. The expansion of the desmopressin market is driven by the increasing number of nocturia cases among elderly men and women. Nocturia is a lower urinary tract symptom which involves the need for passing urine at night, resulting in the disturbance of sleep. As a result, it frequently impacts upon the quality of life (QoL) and wellbeing of individuals. The prevalence increases with the age and has reported to be as high as 77% and 94% in elderly women and men respectively, thus leading to the expansion of the desmopressin market. Desmopressin works as an effective treatment for patients with nocturia. The antidiuretic effect of desmopressin decreases the number of the night voids and prolongation of the sleep period as compared to placebo. However, the market growth of Bivalirudin is hindered by various reasons including the cost and the reluctance to change from existing anti-thrombotic agents used.

Key Players

  • Pfizer, Inc. (US)
    • Company Overview
    • Key Product Offerings
    • Business Strategy
    • SWOT Analysis
    • Financials
  • Hainan Shuangcheng Pharmaceuticals Co. Ltd.
  • AmbioPharm Inc.
  • Abott India Limited (India)
  • The Medicines Company
  • Sun Pharmaceuticals Industries Limited
  • Ferring Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Chengdu Shengnuo Biopharm Co. Ltd.
  • ScinoPharm Taiwan Ltd

Scope and Context

Overview of the Parent Market

Analyst View


The Global Bivalirudin and Desmopressin Market is segmented as follows:

  • By Use Market Size & Y-O-Y Growth Analysis
  • By Region Market Size & Y-O-Y Growth Analysis

Market Dynamics

Supply & Demand Risk

Competitive Landscape

Porter’s Five Force Model

Geographical Economic Activity

Key Players (respective SWOT Analysis) and their Strategies and Product Portfolio

Recent Trends and Developments

Industry Growth Drivers and Challenges

Key Information for Players to establish themselves in current dynamic environment

Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved